News | January 03, 2023
Blacksmith announces merger with Forge Therapeutics
To create leading company developing medicines targeting metalloenzymes
To create leading company developing medicines targeting metalloenzymes
Lumpi-ProVacind is used for the prophylactic immunization of animals against Lumpy Skin Disease, which illicit protection for about one year
The company is one of the most profitable companies manufacturing speciality chemicals in India
Quantori develops solutions on the Databricks Lakehouse Platform providing real-time insights
Krishna Institute of Medical Sciences to consider raising Rs. 300 crores
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Subscribe To Our Newsletter & Stay Updated
